Function suppression type of genetically-modified rhodocytin mutant
AssigneeUniversity of Yamanashi
InventorsTomoyuki Sasaki, Toshiaki Shirai, Katsue Inoue
Life of this patent
Estimating the term…
Abstract
According to the present invention, a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability is provided. According to the present invention, there is provided a method for inhibiting platelet aggregation by a platelet aggregating substance, including administering a pharmaceutical composition including a mutant rhodocytin lacking platelet aggregation ability to a subject in need thereof.
Claims12
A mutant rhodocytin lacking platelet aggregation ability, wherein the mutant rhodocytin comprises 2, 3 or 4 subunits.
A mutant rhodocytin comprising a mutant β subunit having amino acid mutations at one or more positions selected from the group consisting of positions [K53 and R56], [R58 and K60] and [R28 and K31] of β subunit of wild-type rhodocytin.
A mutant rhodocytin comprising a mutant type β subunit having amino acid mutations at either positions [K53 and R56] or [R58 and K60] of β subunit of wild-type rhodocytin.
Dependencies are inferred from the claim text.